Is small cell lung cancer the perfect target for anti- telomerase treatment?

Sarvesvaran, J., Going, J.J., Milroy, R., Kaye, S.B. and Keith, W.N. (1999) Is small cell lung cancer the perfect target for anti- telomerase treatment? Carcinogenesis, 20(8), pp. 1649-1651. (doi: 10.1093/carcin/20.8.1649)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1093/carcin/20.8.1649

Abstract

Small cell lung cancer (SCLC) is common in men and women, has<SUP> </SUP>a very poor prognosis, and is therefore a major cause of premature<SUP> </SUP>mortality. As such, any prospects for improved therapy are of<SUP> </SUP>great significance. The promise of telomerase as a therapeutic<SUP> </SUP>target is now close to realization with extremely encouraging<SUP> </SUP>preclinical studies aimed at the RNA component (hTR) of telomerase.<SUP> </SUP>The rational integration of telomerase therapeutics into clinical<SUP> </SUP>trials will therefore require tumours to be well characterized<SUP> </SUP>for hTR expression. Despite the large number of cancer types<SUP> </SUP>now characterized for telomerase or telomerase component gene<SUP> </SUP>expression, only a handful of SCLC samples have been analysed.<SUP> </SUP>Given the major clinical problem with treating SCLC, we specifically<SUP> </SUP>set out to address the issue of hTR expression in neuroendocrine<SUP> </SUP>tumours. Our study covers 91 pulmonary neuroendocrine tumours<SUP> </SUP>(62 SCLC and 29 carcinoid tumours). We present data to show<SUP> </SUP>that upregulation of the RNA component of telomerase occurs<SUP> </SUP>in 98% of human SCLCs. Interestingly, the less aggressive carcinoid<SUP> </SUP>tumours of the lung had a significantly lower frequency of hTR<SUP> </SUP>expression (<I>P</I> < 0.01). Importantly, we compare hTR expression<SUP> </SUP>in this series to the well characterized biological targets<SUP> </SUP>p53 and BCL2, and show hTR to be expressed more frequently.<SUP> </SUP>Therapies directed at the RNA component of human telomerase<SUP> </SUP>are in active development and these data show SCLC to be a prime<SUP> </SUP>target for such therapies.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Milroy, Dr Robert and Going, Dr James and Keith, Professor Nicol
Authors: Sarvesvaran, J., Going, J.J., Milroy, R., Kaye, S.B., and Keith, W.N.
Subjects:R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Q Science > QH Natural history > QH426 Genetics
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Carcinogenesis
ISSN:0143-3334

University Staff: Request a correction | Enlighten Editors: Update this record